CARNEGIE MELLON UNIVERSITY

GenBio AI launches Phase 1 of the world's first AI-Driven Digital Organism (AIDO), featuring six models for DNA, RNA, Protein, Protein Structure, Single Cell Expression, and Evolutionary Information. These models, unprecedented in speed and efficiency, aim to revolutionize drug discovery, disease understanding, and personalized medicine by simulating and predicting complex biological outcomes.

The University of Utah highlights researchers Dr. Birgit Knoechel, Dr. Nathan Moodie, and Dr. Yuree Noh. Knoechel studies T-cell subsets in T-ALL with a Rally Foundation grant, Moodie leads a CarbonSAFE Phase II project on CO2 storage in Utah, and Noh collaborates on a National Science Foundation project analyzing global surveillance and censorship.

318 H&E-stained duodenal biopsies of varying celiac disease severity and 58 normal duodenum slides were collected, scanned at 40× magnification, and split into training, validation, and test datasets. A CNN model was developed to segment tissue regions and quantify histological features relevant to celiac disease, validated by pathologists. HIFs were correlated with modified Marsh scores, and statistical analysis assessed model performance and feature differences between celiac disease and normal duodenum.

DrugAgent, a multi-agent framework, automates ML programming in drug discovery, leveraging LLMs to perform tasks autonomously, from data acquisition to model selection, enabling pharmaceutical scientists to benefit from AI without extensive coding expertise. It systematically explores diverse ideas and builds domain-specific tools, achieving an F1 score of 0.92 in ADMET prediction using a random forest model, demonstrating its effectiveness in accelerating drug discovery.

Carnegie Mellon University to launch new tuition assistance program, offering free tuition or federal loan-free tuition to students of a certain income level starting next year.

Lameck Beni and Eric Zhao, both CMU Rales Fellows, are developing innovative medical devices. Beni focuses on cancer research, therapy, and diagnosis, while Zhao creates custom prosthetic liners. Their work leverages advanced technologies like lattices and lab-on-a-chip, aiming to improve patient outcomes and accessibility.

Caltech scientists developed a machine learning-driven method for accurately measuring individual particle and molecule masses using complex nanoscale devices, potentially enabling the determination of complete proteome sequences without protein fragmentation.

Pittsburgh Life Sciences Alliance identifies 'Data-Driven Healthcare and Connected Devices' and 'Next-Gen Therapeutics Development and Manufacturing' as growth platforms, leveraging regional strengths in AI, data science, and clinical research.